Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.

17 Feb 2010

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

An international team of researchers has found that adding a humanized monoclonal antibody called daclizumab to standard treatment reduces the number of new or enlarged brain lesions in patients with relapsing multiple sclerosis. This new study was published online Feb. 16, 2010, and in the March edition of the Lancet Neurology.

17 Feb 2010

Researchers adopt new technique to inhibit cancer growth

One of the difficulties of fighting cancer is that drugs often hit other non-cancerous cells, causing patients to get sick. But what if researchers could sneak cancer-fighting particles into just the cancer cells?

17 Feb 2010

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Biogen Idec and Facet Biotech Corporation today announced the publication of Phase 2 data showing that the addition of daclizumab to interferon beta (IFNβ) led to a significant reduction in the number of new or enlarged multiple sclerosis (MS) lesions when compared to IFNβ alone in patients with active relapsing forms of MS.

17 Feb 2010

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Celldex Therapeutics, Inc. today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer.

17 Feb 2010

Diagenode launches SX-8G IP-Star system for epigenetics

Diagenode, an innovative leader providing products and technologies for epigenetics, genomics and diagnostics, and the only provider of complete epigenetics solutions, announced today the launch of its innovative platform for automated epigenetics assays, the SX-8G IP-Star™ system ("IP-Star™).

16 Feb 2010

Narcolepsy is indeed an autoimmune disorder, finds University of Lausanne study

Individuals with the sleep disorder narcolepsy suffer with excessive daytime sleepiness and attacks of muscle paralysis triggered by strong emotions (a condition known as cataplexy).

16 Feb 2010

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Oncogenic retroviruses are a particular family of viruses that can cause some types of cancer. Thierry Heidmann and his colleagues in the CNRS-Institut Gustave Roussy-Université Paris Sud 11 "Rétrovirus endogènes et éléments rétroïdes des eucaryotes supérieurs" Laboratory have studied these viruses. They have identified a "virulence factor" that inhibits the host immune response and allows the virus to spread throughout the body.

16 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Researchers identify potential therapeutic targets for treatment of neuroblastoma

A team of researchers, led by Patrick Mehlen, at Universit- de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma - the most frequent solid tumor in young children- by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks.

15 Feb 2010

Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT

OrbusNeich announced that clinical data presented at the Joint Intervention Meeting (JIM) 2010 in Rome provide further evidence that the company's Genous stent could be a treatment of choice for patients not suitable for long term dual antiplatelet therapy. The investigator initiated, 50 patient, multicenter study evaluated the safety of patients receiving only 10 days dual antiplatelet therapy undergoing stenting with the Genous Bio-engineered R stent. The primary endpoint was the absence of stent thrombosis or any occlusion within three months.

15 Feb 2010

Isogenica enters into agreement with Dstl to develop antimicrobial peptide drugs

Isogenica Ltd today announced that it has entered into an agreement with UK Ministry of Defence agency, the Defence Science and Technology Laboratory. The agreement concerns the development of antimicrobial peptide drugs and follows a successful collaboration to identify highly effective antimicrobial peptides which are active against a broad spectrum of bacteria.

15 Feb 2010

TAP to showcase ambr system at Cell Line Development and Engineering 2010

The Automation Partnership, a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be showcasing its new advanced micro bioreactor system (ambr™) at Cell Line Development and Engineering 2010, February 25-26 in San Francisco, USA.

15 Feb 2010

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

A set of proteins found in our intestines can recognize and kill bacteria that have human blood type molecules on their surfaces, scientists at Emory University School of Medicine have discovered.

15 Feb 2010

Patients receiving female-donor plasma did better than patients receiving male-donor plasma: Study

Three years after the U.S. blood banking industry issued recommendations that discourage transfusing plasma from female donors because of a potential antibody reaction, Duke University Medical Center researchers discovered that female plasma actually may have advantages.

12 Feb 2010

Histone modifications associated with pancreatic cancer development and progression

Specific chemical modifications to proteins called histones, which are found in the nucleus of cells and act as spools around which DNA is wound, can be used to predict prognosis and response to treatment in subsets patients with pancreatic cancer, a study by researchers at UCLA's Jonsson Comprehensive Cancer Center has found.

12 Feb 2010

Anti-PC antibody linked to reduced risk of arteriosclerosis

The chances of suffering a stroke are linked to the presence of a certain type of antibody in the immune system, a new study from Karolinska Institutet shows. The researchers hope to be able to develop a vaccine that can mobilise the body's own defence against arteriosclerosis and stroke.

12 Feb 2010

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.

12 Feb 2010

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

A leading immunology research institute has validated the long-held and controversial hypothesis that antibodies - usually the "good guys" in the body's fight against viruses - instead contribute to severe dengue virus-induced disease, the La Jolla Institute for Allergy & Immunology announced today. The finding has major implications for the development of a first-ever vaccine against dengue virus, a growing public health threat which annually infects 50 to 100 million people worldwide, causing a half million cases of the severest form.

12 Feb 2010

Antibody News and Research

Further Reading

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

Adding daclizumab to standard treatment reduces enlarged brain lesions in patients with relapsing MS

Researchers adopt new technique to inhibit cancer growth

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Diagenode launches SX-8G IP-Star system for epigenetics

Narcolepsy is indeed an autoimmune disorder, finds University of Lausanne study

CNRS-Institut researchers identify 'virulence factor' that inhibits host immune response

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Researchers identify potential therapeutic targets for treatment of neuroblastoma

Genous Bio-engineered R stent beneficial for patients not suitable for long term DAPT

Isogenica enters into agreement with Dstl to develop antimicrobial peptide drugs

TAP to showcase ambr system at Cell Line Development and Engineering 2010

Proteins found in intestines can recognize and kill bacteria that have human blood type molecules

Patients receiving female-donor plasma did better than patients receiving male-donor plasma: Study

Histone modifications associated with pancreatic cancer development and progression

Anti-PC antibody linked to reduced risk of arteriosclerosis

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Antibodies also contribute to severe dengue virus-induced disease, confirms La Jolla Institute for Allergy & Immunology

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News